We also provide evidences that Nogo‐B is a positive regulator of tumor angiogenesis in vivo, and anti‐Nogo‐B antibody inhibits tumor growth in vivo via suppressing tumor angiogenesis, suggesting that Nogo‐B is a potential therapeutic target for tumor angiogenesis. Here, RTN4 is linked to neoplasm.